Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.

MLA

Khan, Muhammad Shahzeb, et al. “Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.” Journal of the American Heart Association, vol. 12, no. 1, Jan. 2023, p. e027652. EBSCOhost, https://doi.org/10.1161/JAHA.122.027652.

APA

Khan, M. S., Butler, J., Anker, S. D., Filippatos, G., Ferreira, J. P., Pocock, S. J., Januzzi, J. L., Piña, I. L., Böhm, M., Ponikowski, P., Verma, S., Brueckmann, M., Vedin, O., Zeller, C., Zannad, F., & Packer, M. (2023). Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. Journal of the American Heart Association, 12(1), e027652. https://doi.org/10.1161/JAHA.122.027652

Chicago

Khan, Muhammad Shahzeb, Javed Butler, Stefan D Anker, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, James L Januzzi, et al. 2023. “Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause.” Journal of the American Heart Association 12 (1): e027652. doi:10.1161/JAHA.122.027652.